P.S. Jayakumar has ceased to be an Independent Director of emcure pharmaceuticals with effect from the close of business hours on July 21, 2026. This development follows the completion of his second consecutive term on the Board, necessitating his departure in accordance with regulatory norms. The change impacts the company's governance structure as he vacated key leadership roles within its board committees.

Consequent to his cessation as a director, Mr. Jayakumar also stepped down from his positions on specific Board Committees effective July 21, 2026. He had served as the Chairman of the Audit Committee and was a Member of both the Nomination and Remuneration Committee and the Risk Management Committee. The Board acknowledged his contributions during his tenure.

The disclosure was made to the exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was formally submitted by Amruta Yangalwar, Company Secretary & Compliance Officer.

Committee Positions Vacated

Emcure Pharmaceuticals and Biological E have received licenses from the Indian Council of Medical Research (ICMR) for three homegrown biomedical technologies intended for commercial use. The licensed portfolio spans critical therapeutic and preventive healthcare areas, including an anti-HPV treatment and advanced vaccines designed to combat typhoid, paratyphoid, and shigella.

ICMR's Technology Transfer Initiative

ICMR's decision to license these indigenously developed technologies to Emcure Pharmaceuticals and Biological E reflects a broader effort to bridge the gap between domestic biomedical research and large-scale commercial healthcare delivery. By partnering with established pharmaceutical entities, ICMR aims to facilitate the wider availability of these innovations to the public.

Licensed Technologies at a Glance

The three biomedical technologies licensed under this arrangement cover distinct but significant disease areas. The following table outlines the key details of the licensed technologies:

Significance of the Licensed Portfolio

The anti-HPV treatment addresses human papillomavirus, a virus linked to cervical cancer and other conditions, representing an important addition to India's oncology and infectious disease management landscape. The advanced vaccines for typhoid and paratyphoid target enteric fever, which continues to pose a public health challenge in several regions. The shigella vaccine addresses a leading cause of bacterial diarrheal disease, particularly relevant in settings with limited sanitation infrastructure.

These technologies, developed domestically by ICMR, underscore India's growing capability in indigenous biomedical innovation. The commercial licensing to Emcure Pharmaceuticals and Biological E is expected to support the translation of these research outcomes into accessible healthcare products.